Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 studyResearch in context

Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 studyResearch in context

Summary: Background: Gene therapy, successfully used in rare, monogenetic disorders, may prove to be a durable management approach for common, polygenetic conditions, including neovascular age-related macular degeneration (nAMD). Repeated injections, oftentimes monthly, and possibly for decades, of...

Full description

Bibliographic Details
Main Authors: Arshad M. Khanani, David S. Boyer, Charles C. Wykoff, Carl D. Regillo, Brandon G. Busbee, Dante Pieramici, Carl J. Danzig, Brian C. Joondeph, James C. Major, Jr., Adam Turpcu, Szilárd Kiss
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:EClinicalMedicine
Subjects:
Neovascular age-related macular degeneration
Gene therapy
Anti-VEGF
Ixoberogene soroparvovec
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023005710

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023005710

Similar Items